The major findings of this study suggests that individuals with CF do not demonstrate cardiac and peripheral vascular hemodynamic responsiveness to the short-acting β2AR selective-agonist albuterol that mirror normal responses of healthy individuals. This evidence concerns the gene ADRB2 and cystic fibrosis.